Press Releases

Sign up for Email Alerts Press Release RSS

02/26/2018
Bristol-Myers Squibb Announces Expansion of the International Immuno-Oncology Network (II-ON) with Addition of Yale Cancer Center
Term:R&D News
Language:English
02/14/2018
Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214
Term:Partnering News
Language:English
02/08/2018
Bristol-Myers Squibb to Take Part in Leerink 7th Annual Global Healthcare Conference
Term:Corporate/Financial News
Language:English
02/05/2018
Statement: Bristol-Myers Squibb Validates Predictive Role of Tumor Mutation Burden in Phase 3 CheckMate -227 Program in First-Line Non-Small Cell Lung Cancer
Term:Corporate/Financial News
Language:English
02/05/2018
Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)
Term:Opdivo
Language:English
02/05/2018
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
Term:Corporate/Financial News
Language:English
01/22/2018
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Term:Corporate/Financial News
Language:English
01/20/2018
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
Term:Corporate/Financial News
Language:English
01/03/2018
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Term:Corporate/Financial News
Language:English
12/20/2017
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm